Valeant Hit With Shareholder Suit Over $3B Biovail Deal

Valeant Pharmaceuticals International Inc. and its directors have been hit with a shareholder class action seeking to block the company's $3.2 billion deal to merge with Biovail Corp....

Already a subscriber? Click here to view full article